These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 27220960)

  • 1. Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH Trial.
    Zhu AX; Kang YK; Rosmorduc O; Evans TR; Santoro A; Ross P; Gane E; Vogel A; Jeffers M; Meinhardt G; Peña CE
    Clin Cancer Res; 2016 Oct; 22(19):4870-4879. PubMed ID: 27220960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma.
    Zhu AX; Rosmorduc O; Evans TR; Ross PJ; Santoro A; Carrilho FJ; Bruix J; Qin S; Thuluvath PJ; Llovet JM; Leberre MA; Jensen M; Meinhardt G; Kang YK
    J Clin Oncol; 2015 Feb; 33(6):559-66. PubMed ID: 25547503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma.
    Thomas MB; Garrett-Mayer E; Anis M; Anderton K; Bentz T; Edwards A; Brisendine A; Weiss G; Siegel AB; Bendell J; Baron A; Duddalwar V; El-Khoueiry A
    Oncology; 2018; 94(6):329-339. PubMed ID: 29719302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-term and long-term efficacy of 7 targeted therapies for the treatment of advanced hepatocellular carcinoma: a network meta-analysis: Efficacy of 7 targeted therapies for AHCC.
    Niu M; Hong D; Ma TC; Chen XW; Han JH; Sun J; Xu K
    Medicine (Baltimore); 2016 Dec; 95(49):e5591. PubMed ID: 27930578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma.
    Yada M; Masumoto A; Motomura K; Tajiri H; Morita Y; Suzuki H; Senju T; Koyanagi T
    World J Gastroenterol; 2014 Sep; 20(35):12581-7. PubMed ID: 25253961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma.
    Llovet JM; Peña CE; Lathia CD; Shan M; Meinhardt G; Bruix J;
    Clin Cancer Res; 2012 Apr; 18(8):2290-300. PubMed ID: 22374331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease.
    Yau T; Wong H; Chan P; Yao TJ; Pang R; Cheung TT; Fan ST; Poon RT
    Invest New Drugs; 2012 Dec; 30(6):2384-90. PubMed ID: 22402942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
    Vilgrain V; Pereira H; Assenat E; Guiu B; Ilonca AD; Pageaux GP; Sibert A; Bouattour M; Lebtahi R; Allaham W; Barraud H; Laurent V; Mathias E; Bronowicki JP; Tasu JP; Perdrisot R; Silvain C; Gerolami R; Mundler O; Seitz JF; Vidal V; Aubé C; Oberti F; Couturier O; Brenot-Rossi I; Raoul JL; Sarran A; Costentin C; Itti E; Luciani A; Adam R; Lewin M; Samuel D; Ronot M; Dinut A; Castera L; Chatellier G;
    Lancet Oncol; 2017 Dec; 18(12):1624-1636. PubMed ID: 29107679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial.
    Cheng AL; Kang YK; Lin DY; Park JW; Kudo M; Qin S; Chung HC; Song X; Xu J; Poggi G; Omata M; Pitman Lowenthal S; Lanzalone S; Yang L; Lechuga MJ; Raymond E
    J Clin Oncol; 2013 Nov; 31(32):4067-75. PubMed ID: 24081937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    Bruix J; Takayama T; Mazzaferro V; Chau GY; Yang J; Kudo M; Cai J; Poon RT; Han KH; Tak WY; Lee HC; Song T; Roayaie S; Bolondi L; Lee KS; Makuuchi M; Souza F; Berre MA; Meinhardt G; Llovet JM;
    Lancet Oncol; 2015 Oct; 16(13):1344-54. PubMed ID: 26361969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma.
    Ciuleanu T; Bazin I; Lungulescu D; Miron L; Bondarenko I; Deptala A; Rodriguez-Torres M; Giantonio B; Fox NL; Wissel P; Egger J; Ding M; Kalyani RN; Humphreys R; Gribbin M; Sun W
    Ann Oncol; 2016 Apr; 27(4):680-7. PubMed ID: 26802147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.
    Wu FX; Chen J; Bai T; Zhu SL; Yang TB; Qi LN; Zou L; Li ZH; Ye JZ; Li LQ
    BMC Cancer; 2017 Sep; 17(1):645. PubMed ID: 28899349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib.
    Oh CR; Kong SY; Im HS; Kim HJ; Kim MK; Yoon KA; Cho EH; Jang JH; Lee J; Kang J; Park SR; Ryoo BY
    BMC Cancer; 2019 Apr; 19(1):292. PubMed ID: 30935424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II Study of First-Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma.
    Abou-Alfa GK; Blanc JF; Miles S; Ganten T; Trojan J; Cebon J; Liem AK; Lipton L; Gupta C; Wu B; Bass M; Hollywood E; Ma J; Bradley M; Litten J; Saltz LB
    Oncologist; 2017 Jul; 22(7):780-e65. PubMed ID: 28592620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyproheptadine significantly improves the overall and progression-free survival of sorafenib-treated advanced HCC patients.
    Feng YM; Feng CW; Lu CL; Lee MY; Chen CY; Chen SC
    Jpn J Clin Oncol; 2015 Apr; 45(4):336-42. PubMed ID: 25646358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of sorafenib combined with low-dose interferon therapy for advanced hepatocellular carcinoma: a pilot study.
    Itokawa N; Atsukawa M; Tsubota A; Okubo T; Arai T; Nakagawa A; Kondo C; Iwakiri K
    Int J Clin Oncol; 2016 Aug; 21(4):676-683. PubMed ID: 26701173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum cytokine profiles predict survival benefits in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective cohort study.
    Hayashi T; Yamashita T; Terashima T; Suda T; Okada H; Asahina Y; Hayashi T; Hara Y; Nio K; Sunagozaka H; Takatori H; Arai K; Sakai Y; Yamashita T; Mizukoshi E; Honda M; Kaneko S
    BMC Cancer; 2017 Dec; 17(1):870. PubMed ID: 29258450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Higher serum interleukin-17A levels as a potential biomarker for predicting early disease progression in patients with hepatitis B virus-associated advanced hepatocellular carcinoma treated with sorafenib.
    Cho HJ; Kim SS; Nam JS; Oh MJ; Kang DR; Kim JK; Lee JH; Kim B; Yang MJ; Hwang JC; Lim SG; Shin SJ; Lee KM; Yoo BM; Lee KJ; Cho SW; Cheong JY
    Cytokine; 2017 Jul; 95():118-125. PubMed ID: 28260649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma.
    Finn RS; Poon RT; Yau T; Klümpen HJ; Chen LT; Kang YK; Kim TY; Gomez-Martin C; Rodriguez-Lope C; Kunz T; Paquet T; Brandt U; Sellami D; Bruix J
    J Hepatol; 2013 Dec; 59(6):1271-7. PubMed ID: 23928403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies.
    Bruix J; Cheng AL; Meinhardt G; Nakajima K; De Sanctis Y; Llovet J
    J Hepatol; 2017 Nov; 67(5):999-1008. PubMed ID: 28687477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.